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ABSTRACT
Pre-mRNA splicing is performed by the spliceo-
some. SR proteins in this macromolecular complex
are essential for both constitutive and alternative
splicing. By using the SR-related protein ZNF265
as bait in a yeast two-hybrid screen, we pulled out
the uncharacterized human protein XE7, which is
encoded by a pseudoautosomal gene. XE7 had been
identified in a large-scale proteomic analysis of
the human spliceosome. It consists of two differ-
ent isoforms produced by alternative splicing. The
arginine/serine (RS)-rich region in the larger of
these suggests a role in mRNA processing. Herein
we show for the first time that XE7 is an alternative
splicing regulator. XE7 interacts with ZNF265, as
well as with the essential SR protein ASF/SF2. The
RS-rich region of XE7 dictates both interactions.
We show that XE7 localizes in the nucleus of human
cells, where it colocalizes with both ZNF265 and
ASF/SF2, as well as with other SR proteins, in
speckles. We also demonstrate that XE7 influences
alternative splice site selection of pre-mRNAs from
CD44, Tra2-b1 and SRp20 minigenes. We have
thus shown that the spliceosomal component XE7
resembles an SR-related splicing protein, and can
influence alternative splicing.
INTRODUCTION
Removal of introns from pre-mRNAs is performed by the
spliceosome, a large complex consisting of ﬁve small nuclear
ribonucleoprotein particles (snRNPs; U1, U2, U4, U5
and U6) and various other proteins. Puriﬁcation and analysis
of the multiple proteins in the spliceosome (1–4) shows
that these can be divided into different groups: SR proteins,
non-snRNP spliceosome assembly proteins, U1, U2, U5 and
U4/U6 snRNP speciﬁc proteins, and Sm/LSm core proteins.
Members of the SR family include ASF/SF2, SC35 and
SRp20. Each is required for constitutive splicing and can
regulate alternative splicing. SR proteins are essential spli-
cing factors since they can complement splicing-deﬁcient
S100 extracts. They contain one or more RNA recognition
motifs (RRMs) and a C-terminal arginine/serine (RS)-rich
domain in which the serine residues are phosphorylated. As
well as binding to other proteins in the spliceosome via
their RS domains, certain SR proteins can bind to the pre-
mRNA directly (5). There is also a class of splicing factors
known as SR-related proteins, which contain RS-domains
of varying length. Unlike SR-proteins these may or may not
contain an RRM, and instead may contain other domains such
as a DEXD/H Box or a zinc ﬁnger. U2AF
35, U1-70K and
SRm160 are all examples of SR-related proteins (6) and
recently many other proteins have been shown to belong to
this family (7–14). SR proteins are distinguished from
SR-related proteins by their speciﬁc domain structure
(RRM domain/s followed by RS domain) and activities in
splicing-deﬁcient S100 extracts.
We have previously identiﬁed the zinc ﬁnger- and RS
domain-containing protein ZNF265 as being a novel compon-
ent of the mRNA processing machinery (14). This SR-related
family member immunoprecipitates with mRNA from
splicing extracts, interacts with U1-70K and U2AF
35 and
regulates splicing of Tra2b1 transcripts in a dose-dependent
manner. ZNF265 exists in at least two alternatively-spliced
forms, with different C-termini. The short form, in this
paper referred to as ZNF265SF (GenBank Accession number
NP_005446), differs by 10 amino acids from the long form,
here referred to as ZNF265LF (GenBank Accession number
NP_976225), and includes an alternative exon 11, containing
a stop codon.
In a yeast library screen using ZNF265SF as bait we pulled
out the novel protein XE7. Its gene, XE7, is pseudoautosomal
(15), and generates two alternatively spliced isoforms, one
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The latter includes an exon that introduces an in-frame stop
codon, generating a truncated protein. Expression of the
gene is ubiquitous. The long isoform of XE7 is RS rich
with 30% of the last 311 amino acids being either arginine
or serine (16). This suggests that XE7 might be involved in
RNA processing. XE7 was identiﬁed in a large-scale proteo-
mic analysis of the human spliceosome, but under the altern-
ative name ‘B-lymphocyte antigen precursor’ (4). To date, no
functional studies on XE7 have been carried out.
Here we describe, for the ﬁrst time, the characterization of
XE7 and show that it is a regulator of alternative splicing.
MATERIALS AND METHODS
Plasmid constructs and cloning
Plasmids were made using cDNA generated from Calu-6
cells with Superscript II (Invitrogen). PCR products were
inserted into pGEM to generate pGEM-XE7, pGEM-ASF/
SF2, pGEM-ZNF265SF and pGEM-ZNF265LF. Full-length
XE7 and XE7DRS (generated using primers 50-aaaaaagaattct-
aatggcagcggctaccatcgtg-30 and 50-aaaaaagagctcgcttgtgccggtc-
agcaag-30) were ligated into pGBK, pGAD and pCMV-HA.
Full-length ASF/SF2 was ligated into pEGFP-C2 to generate
EGFP (enhanced green ﬂuorescence protein)-ASF/SF2.
pACT-ASF/SF2 (ASF/SF2 in DNA-activation domain
plasmid) was kindly provided by N. Hastie and R. Davies. To
generate pGBK-ZNF265SF the primers 50-catatgatgtcgaccaag-
aatttccga-30 and 50-gaattcgtagtggtgttccgta-30 were used and to
generate pGBK-ZNF265LF we used 50- catatgatgtcgaccaagaa-
tttccga-30 and 50-gaattcgcttcatgcactgtact-30. pEGFP-ZNF265SF
was generated using primers 50-ctcgagtatgtcgaccaagaattt-30
and 50-gaattcgtagtggtgttccgta-30 and pEGFP-ZNF265LF by
using 50-ctcgagtatgtcgaccaagaattt-30 and 50-gaattcgcttcatgca-
ctgtact-30. All ZNF265LF fragments were cloned by gel-
purifying the desired fragment, after PCR, to distinguish
the LF from the SF. pCMV-Myc-ZNF265SF was generated
using primers 50-aaaaaagaattcatatgtcgaccaagaattttccgagt-30
and 50-aaaaaactcgaggcttgactcacaggctttatttaca-30.
Yeast two-hybrid and library screen
Saccharomyces cerevisiae strain AH109 was grown in YPDA
medium (20 g/l peptone, 10 g/l yeast extract, 20 g/l glucose,
0.03 g/l adenine) and cells were transformed with binding
and activation domain plasmids using the lithium acetate
method according to the MATCHMAKER two-hybrid
system (Clontech). The cells were subsequently plated on
synthetic deﬁned medium deﬁcient in adenine, histidine,
leucine and tryptophan [SD ( A/ H/ L/ W)] and allowed
to grow for 3–5 days at 30 C. After re-streaking, true positive
colonies were identiﬁed by checking for b-galactosidase pro-
duction from the lacZ reporter gene using the colony-lift ﬁlter
assay. Results were conﬁrmed by a liquid culture assay using
Galacton-Star reaction mixture (Clontech). A library screen
was performed by mating a culture of S.cerevisiae AH109
pretransformed with pGBK-XE7 (bait) with a pretransformed
foetal brain cDNA library (Clontech). After incubating the
mixture with gentle swirling for 24 h at 30 C, the cells were
plated on SD ( A/ H/ L/ W) and incubated at 30 C for
18 days. To identify true positives, a b-galactosidase ﬁlter
assay was employed as described above and positive clones
were restreaked several times. Positive clones were rescued,
plasmid was extracted and transformation was conducted by
electroporation into bacterial JM109 cells. After plasmid
extraction, clones were sent for sequencing to the Australian
Genomics Research Facility using the primer GAL4AD
(50-taccactacaatggatg-30).
Cell culture
Cell lines were obtained from the American Type Culture
Collection and cultured at 37 C under 5% CO2. Calu-6
cells were cultured in Minimum Essential Medium
(Invitrogen), supplemented with 0.1 mM non-essential
amino acids. HeLa cells and HEK293 cells were cultured
in DMEM (Invitrogen), supplemented with 0.1 mM non-
essential amino acids and 1.0 mM sodium pyruvate. 10%
fetal calf serum (FCS; Invitrogen) and penicillin/
streptomycin (5000 U/ml; Invitrogen) were added to all
media. Constructs were transfected by Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
For the transcription inhibition experiment, cells were treated
with a-amanitin (50 mg/ml) for 8 h.
Antibodies
Polyclonal antibodies to XE7 were generated by Alpha
Diagnostics by inoculating New Zealand white rabbits with
a KLH-tagged peptide (TGDGLADRHKRERS) correspond-
ing to amino acids 591–604 of XE7 (GenBank Accession
Number Q02040). Antiserum was afﬁnity puriﬁed by immob-
ilizing peptide antigen on Sepharose-4B beads followed by
column chromatography. Mouse monoclonal anti-SR (1H4;
sc-13509) was from Santa Cruz and rabbit polyclonal anti-
haemagglutinin (HA) was from Clontech. Mouse monoclonal
anti-cMyc (clone 9E10) was from Sigma. Mouse monoclonal
anti-GFP was from Clontech and Roche Diagnostics. Second-
ary antibodies were: Alexa Fluor 488 goat anti-mouse IgG
and Alexa Fluor 594 goat anti-rabbit or anti-mouse IgG (all
from Molecular Probes), horseradish peroxidase conjugate
of goat anti-mouse or anti-rabbit IgG (Amersham Pharmacia
Biotech Inc).
Immunofluorescence
For visualization of ﬂuorescence, cells were cultured on
Lab-Tek II chamber slides (Nalge Nunc International) and
ﬁxed with 100% ice-cold methanol for 1 min. After blocking
with either 5% BSA or 10% goat serum in phosphate-
buffered saline (PBS) for 1 h, the primary antibodies were
applied, followed by the secondary antibodies for 1 h each.
Cells were then stained with 300 nM 40,6-diamidino-2-
phenylindole dihydrochloride (DAPI) (Molecular Probes)
before being mounted with gelatine/glycerol in PBS,
50:50 vol/vol (Sigma). Two- or three-channel ﬂuorescent
images were acquired on a Zeiss Axioplan 2 microscope.
Coimmunoprecipitation and western blotting
Cell extracts from 10
7 HeLa or Calu-6 cells were prepared
using the mammalian cell lysis kit (Sigma). Approximately
500 mg of the extract was precleared with 20 ml Protein A
agarose, then 3 mg antibody was added. After 4 h of
incubation at 4 C, 50 ml protein A agarose was added.
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frequent mixing, washed ﬁve times with PBS and resolved by
12% SDS–PAGE. Proteins were electroblotted on to a PVDF
membrane (Perkin Elmer). Membranes were blocked for 1 h
in 5% blocking agent (Amersham Pharmacia), followed by
incubation with primary antibody for 1 h and subsequent
incubation with secondary antibody for 1 h, before detection
by enhanced chemiluminescence (ECL) reagents (Amersham
Pharmacia) according to the manufacturer’s instructions. All
washes were with PBS-Tween.
Splicing assays
In vivo splicing assays were performed essentially as
described (17). Brieﬂy, a splicing reporter minigene was
cotransfected with an increasing amount of XE7 expression
construct (pCMV-HA-XE7) in HeLa or HEK293 cells.
Empty pCMV-HA plasmids were added to ensure that
the same amount of DNA was transfected. Additional
EGFP-ASF/SF2 plasmid (1 mg) was added where indicated.
Twenty hours after transfection RNA was isolated using
QIAGEN RNAeasy columns. Reverse transcriptase (RT)-
PCR for the CD44 minigene was performed using primers
N3INS (50-ctcccgggccacctccagtgcc-30) and N5INS (50’-
gagggatccgcttcctgcccc-30) and a program involving 30 cycles
of 94 C for 20 s, 68 C for 30 s and 72 C for 40 s. For Tra2b1
we used primer pCR3.1-RT-Rev (50-gccctctagactcgagctcga-30)
for the RT and primers MGTra-Bam (50-gggccagttgggcgacc-
ggcgcgtcgtgcgcgggg-30) and MGTra-R-Xho (50-gggctcgagtac-
ccgattcccaacatgacg-30) for the PCR consisting of 35 cycles
of 94  for 20 s, 65  for 20 s and 72  for 40 s. For SRp20
we used primers T7 (50-taatacgactcactataggg-30) and X16R
(50-cctggtcgacactctagatttcctttcatttgacc-30) for 30 cycles of
94  for 50 s, 55  for 50 s and 72  for 1 min. The PCR products
were analysed with either a 2% agarose gel or a 6% polyacryl-
amide gel and the splicing pattern was quantiﬁed using the
Image J program (Java). To conﬁrm results some samples
from the Tra2b1 and SRp20 splicing assays were also
quantiﬁed with the DNA 1000 chip from the 2100 Bioanalyzer
(Agilent Technologies).
RESULTS
Alignment of the RS-rich region of XE7 with the
RS domain of SR/SR-related proteins
Comparison of the very RS-rich C-terminal of XE7 with the
RS domain of various splicing proteins, including ZNF265
and ASF/SF2, showed that XE7 is most similar to SC35
and SRp55, and least similar to ASF/SF2 (Figure 1). The
comparison also showed the strong dipeptide conservation
amongst RS domain containing/RS-rich splicing proteins.
By having a large RS-rich region, XE7 is similar in structure
to other SR-related splicing factors, such as SRm160 (18) and
SRrp53 (7) (data not shown).
Subcellular localization of XE7
For intracellular localization studies we produced a poly-
clonal anti-XE7 antibody directed towards the C-terminus
of the long isoform of XE7 (just 50 of the RS-rich region)
and found that endogenous XE7 was expressed in the nucleus
of HeLa cells (Figure 2A, i). The staining from the XE7 anti-
body suggested that XE7 was also weakly expressed in the
cytoplasm. However, competition with the XE7 oligopeptide
antigen did reduce staining in the nucleus, showing the spe-
ciﬁcity of the antibody and suggested to us that the staining
in the cytoplasm was only background (Figure 2A, ii).
When performing immunolocalization using only the second-
ary antibody as a control we also noted staining in the
cytoplasm, conﬁrming that the cytoplasmic staining is only
background (data not shown). XE7 also colocalized with
SR proteins in speckles in the nucleus of Calu-6 cells
(Figure 2B). XE7 localization was modiﬁed by inhibition of
transcription using a-amanitin, and resulted in colocaliza-
tion of XE7 with SC35 in well-deﬁned round compart-
ments (Figure 2C). This tighter association with round
speckles upon inhibition of transcription is typical for other
SR-proteins.
Subcellular localization of mutant XE7
To determine which part of XE7 is responsible for its nuclear
localization we used pCMV-HA constructs of XE7 and of
XE7 with the RS-rich region deleted (XE7DRS). Figure 3A
shows a schematic representation of XE7 and the constructs
used are depicted in Figure 3B and C (left panels). XE7
was again found exclusively in the nucleus and exhibited
a speckle-like pattern (Figure 3B). In contrast XE7DRS
was found in the perinuclear region of the cytoplasm
(Figure 3C), suggesting that the RS-rich region is responsible
for XE7’s nuclear localization. Localization of the short form
of XE7 was also determined with a pCMV-HA construct and
we found that the cellular localization was the same as for
XE7DRS (data not shown).
Figure 1. Strong dipeptide conservation between SR and SR-related proteins. Alignment of part of the RS-rich region of XE7 with that of SR/SR-related
proteins. Black boxes show regions with >53% homology.
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By yeast two-hybrid assay XE7 displayed a positive interac-
tion with both forms of ZNF265, as determined by growth on
SD ( L/ W/ A/ H) plates and the production of blue pre-
cipitate on a b-galactosidase ﬁlter assay (Figure 4, i and ii).
Deletion of the RS-rich region from XE7 abolished the
interaction (Figure 4, iii). To identify other proteins that inter-
act with XE7 a library screen with a human brain cDNA
library was performed using XE7 as bait. At least 3.5 · 10
6
colonies were screened and 30 positive clones were rescued
and sequenced. We found that XE7 also interacts with the
well-characterized SR protein ASF/SF2 (Figure 4, iv). This
interaction was abolished when an XE7 construct without
the RS-rich region was transformed together with ASF/SF2
(Figure 4, v). We also tested the ability of XE7 to interact
with a number of other splicing proteins in a head to head
yeast-two hybrid assay and found that XE7 does not interact
with U1-70K, SC35, SRp20 (Figure 4, vi,vii and viii),
U2AF
35 or U2AF
65 (data not shown). T-antigen/p53 and
T-antigen/LamC were used as positive and negative controls
(Figure 4, ix and x).
Next, we performed coimmunoprecipitation (co-IP) studies
to conﬁrm the interaction between XE7 and ZNF265 in HeLa
and Calu-6 cells and between XE7 and ASF/SF2 in HeLa
cells. A cell extract was prepared from cells transfected
with pCMV-HA-XE7 and pCMV-Myc-ZNF265SF. Using
an antibody towards the Myc epitope tag and Protein A
agarose in the immunoprecipitation, we were able to detect
HA-XE7 in the western blot (Figure 5A, lane 2). The XE7
and ZNF265SF association was speciﬁc since XE7 was
absent in the control immunoprecipitate obtained using
mouse IgG (Sigma) (Figure 5A, lane 3). A Calu-6 cell extract
transfected with pCMV-HA-XE7 and pEGFP-ZNF265SF
was used in another co-IP. With an HA antibody and Protein
A agarose we were able to pull down EGFP-ZNF265SF in the
immunoprecipitate (Figure 5A, lane 4). ZNF265SF was
absent in the control immunoprecipitate obtained using rabbit
IgG, again showing the speciﬁcity of the XE7 and ZNF265SF
association (Figure 5A, lane 6). For the XE7–ASF/SF2
interaction, cells were transfected with pCMV-HA-XE7 and
pEGFP-ASF/SF2 and incubated with GFP antibody and Pro-
tein A agarose. In a western blot of the immunoprecipitate
HA-XE7 was detected using an HA antibody (Figure 5B,
lane 1). The presence of ASF/SF2 in the immunoprecipitate
was shown by incubating the extract with a GFP antibody
together with Protein A agarose, and performing the western
blot with a GFP antibody (Figure 5B, lane 5). Association of
XE7 and ASF/SF2 was speciﬁc, since XE7 as well as ASF/
SF2 were absent in the control immunoprecipitate using
IgG mouse (Figure 5B, lanes 3 and 6). These results conﬁrm
the interaction of XE7 with ASF/SF2 and the short form of
ZNF265.
Figure 2. Localization of XE7 in the nucleus (A) Endogenous localization of XE7 in HeLa cells. XE7 was detected with anti-XE7 rabbit polyclonal antibody (i).
XE7 oligopeptide antigen (5 mg/ml) competes out XE7 (ii). (B) Colocalization of endogenous XE7 and SR proteins in Calu-6 cells using anti-XE7 and anti-SR.
Yellow in the merged image indicates colocalization of XE7 with SR-proteins. (C) Effect of blocking transcription. HeLa cells transfected with pCMV-HA-XE7
were treated with a-amanitin (50 mg/ml) for 8 h, followed by addition of anti-HA and anti-SC35 antibodies. Yellow in the merged image indicates colocalization
of XE7 with SC35 in transcriptionally inactive cells. The nucleus was stained with DAPI. Scale bars: 5 mm.
Nucleic Acids Research, 2006, Vol. 34, No. 17 4979XE7 colocalizes with ZNF265 isoforms and ASF/SF2
ZNF265 has a highly diffuse localization in the nucleus, thus
obscuring a speckled pattern somewhat. However, we were
able to detect a degree of speciﬁc colocalization of ZNF265
(both isoforms) with XE7 in HeLa cells, using pCMV-HA-
XE7 and EGFP-ZNF265 constructs, which we have high-
lighted with arrows (Figure 6A and B). Using HA-XE7 and
EGFP-ASF/SF2 constructs we found extensive colocalization
of XE7 and ASF/SF2 in nuclear speckles of HeLa cells
(Figure 6C) and HEK293 cells (data not shown).
XE7 can influence alternative splice site selection
To further characterize XE7 we conducted in vivo splicing
assays to test the ability of XE7 to inﬂuence alternative spli-
cing. Several reporters containing alternative exons ﬂanked
by constitutive exons (minigenes) (Figure 7A) were transfec-
ted into HeLa cells with increasing amounts of pCMV-HA-
XE7. After RNA extraction, RT–PCR was performed with
primers directed at sequences located in the ﬂanking con-
stitutive exons. Figure 7B shows representative 6% polyac-
rylamide gels from the splicing assays. The most signiﬁcant
effect of XE7 was seen with the minigene CD44. When add-
ing an increasing amount of XE7, inclusion of exon v5 in the
pre-mRNA increased from 2% up to a maximum of 27%
(Figure 7C). Overexpression of XE7 had the opposite effect
on the Tra2b1 minigene, resulting in a reduction in exon 2
inclusion from 40 to 12%, so leading to a decrease in the pro-
duction of the b4 alternatively spliced isoform (Figure 7C).
The same effect on Tra2b1 was also seen with ZNF265
(14). Production of the b3 form represents <0.5% of total
in HeLa cells and we could only detect this form using the
more sensitive 2100 Bioanalyzer. Results showed that XE7
does not inﬂuence the abundance of the b3 form (data not
shown). We also tested if ZNF265 could inﬂuence the effect
XE7 has on splicing of Tra2b1 pre-mRNA by adding a
constant amount (2 mg) of ZNF265 to the assay. However,
this showed that ZNF265 inﬂuences Tra2b1 splicing inde-
pendently of XE7 and does not affect the splicing performed
by XE7 (data not shown). It is thus unlikely that XE7 and
ZNF265 have a synergistic effect.
The ability of XE7 to inﬂuence the alternative splice
pattern of SRp20 was tested in HEK293 cells. The SRp20
minigene construct is shown in Figure 8A, and 8B shows
representative agarose gels. When adding an increasing
amount of XE7, exon 4 inclusion for SRp20 decreased
from 30 to 5% (Figure 8C, i). This effect on SRp20 was sim-
ilar to that of ASF/SF2 on the same minigene (19). When the
XE7-SRp20 splicing reaction was supplemented with a con-
stant amount of ASF/SF2, exon 4 inclusion decreased even
Figure 3. Cellular localization of mutant XE7. (A) XE7 pre-mRNA. The exons are shown as yellow boxes and introns as horizontal lines. The blue and green
lines connecting the exons indicate the splicing patterns, either including or omitting exon 5. The blue lines depict inclusion of the alternative exon (exon 5),
resulting in a premature stop codon and leading to production of the short isoform of XE7. The green lines show production of the long isoform. The start and
stop codons are marked with arrows. (B) Full-length XE7 is localized to nuclear speckles in HeLa cells. A schematic representation of the full-length construct
used is shown on the left. (C) Deletion of the RS-rich region causes XE7 to localize to the perinuclear region of the cytoplasm. XE7DRS indicates the XE7 form
with the RS-rich region deleted, shown on the left. Scale bars: 10 mm.
4980 Nucleic Acids Research, 2006, Vol. 34, No. 17Figure 5. Interaction of XE7 with ZNF265SF and with ASF/SF2 by coimmunoprecipitation. (A) Coimmunoprecipitation of XE7 and ZNF265SF. HeLa cells
were transfected with pCMV-HA-XE7 and pCMV-Myc-ZNF265SF, and Calu-6 cells with pCMV-HA-XE7 and pEGFP-ZNF265SF and cell extracts (500 mg)
immunoprecipitated with 5 mg antibodies or control IgG (negative control) (lanes 3 and 6) using Protein A agarose. Ten microlitres of the complexes were
resolved on SDS–PAGE gel, blotted and the presence of XE7 was confirmed with anti-HA antibody (lane 2). The presence of ZNF265SF was confirmed with a
GFP antibody (lane 4). Positive control was cell extract only (lanes 1 and 5). (B) Coimmunoprecipitation of XE7 and ASF/SF2. HeLa cells were transfected with
pCMV-HA-XE7 and EGFP-ASF/SF2 and cell extracts (500 mg) were immunoprecipitated with 5 mg antibodies or control IgG (lanes 3 and 6) using Protein A
agarose. Ten microlitres of the complexes were resolved on SDS–PAGE gel, blotted, and the presence of HA-XE7 was confirmed with anti-HA (lane 1). Positive
control was cell extract alone (lane 2). The presence of ASF/SF2 was shown when incubating the cell extract with anti-GFP in the immunoprecipitation, followed
by detection of the blot with the same antibody (lane 5, upper band). Positive control for ASF/SF2 was cell extract alone (lane 4).
Figure 4. Interaction of XE7 with ZNF265 and ASF/SF2 in yeast two-hybrid assays. Yeast were cotransformed with DNA-binding-plasmids (vector pGBK ¼
bait) and activation-plasmids (vector pGAD or pACT ¼prey) encoding the proteins indicated, and colonies were grown on SD ( A/ H/ L/ W) dropout plates
prior to b-galactosidase assay. p53 and T-antigen interaction was used as a positive control, and T-antigen and LamC as negative control. ZNF265SF ¼ ZNF265
short form, ZNF265LF ¼ ZNF265 long form. XE7DRS ¼ XE7 with the RS-rich region deleted.
Nucleic Acids Research, 2006, Vol. 34, No. 17 4981more (Figure 8C, ii), demonstrating that XE7 and ASF/SF2
have a synergistic effect. XE7 did not inﬂuence the splicing
pattern of the minigene SMN2 (data not shown).
DISCUSSION
We describe the initial characterization of the protein XE7,
encoded by one of the 24 genes (cloned or putative) located
in the pseudoautosomal region 1 (PAR1) near the terminal of
the short arm of the X and Y chromosomes. The human
PAR1 is essential for meiotic pairing and recombination,
and its deletion causes male sterility. Genes in the
pseudoautosomal region escape the process of X-inactivation
and thus two active copies of each gene are required for
normal function in both males and females. Over 15 putative
orthologues for XE7 have been found, ranging from
Drosophila melanogaster (34% homology), to Canis familiaris
(88% homology) and Macaca mulatta (97% homology).
Little is known about the function of individual proteins
from the PAR1 genes. Ours represents the ﬁrst report of
a protein expressed from a pseudoautosomal gene that
functions in alternative splicing.
XE7 was identiﬁed in 1992 (15,16) and later that year
the predicted amino acid sequence of a protein termed
B-lymphocyte antigen precursor/721P was reported (20).
B-lymphocyte antigen precursor was shown to be a plasma-
membrane-associated glycoprotein, expressed on activated
lymphocytes, most vascular endothelia and syncytiotropho-
blasts (20). The sequence of B-lymphocyte antigen precursor
is the same as that of XE7 up to residue 460, where a frame-
shift in B-lymphocyte antigen precursor results in a different
C-terminus. While it is possible that this is a genetic variant,
it is more likely that this published sequence contains a
sequencing error.
In support of our ﬁndings, XE7 was found recently in
the human spliceosome, and was listed under the name
B-lymphocyte antigen precursor (SWISS_PROT: Q02040).
Herein we show that XE7 is localized to speckles in the
nucleus of human cells and that localization is most likely
due to the RS-rich region, as has been found for many
other RS-domain-containing proteins (11,21–23). Speckles
(also termed interchromatin granule clusters) are compart-
ments that store pre-mRNA processing factors [for a review
see (24)]. Our observation that localization of XE7 was
modiﬁed from nuclear speckles into more deﬁned compart-
ments in transcriptionally inactive cells has been shown for
other splicing factors (24–27). It has also been shown that
SC35 and the large subunit of RNA polymerase II accumulate
simultaneously in these large speckled domains that lack
interconnections (28), and in this study we show that XE7
colocalizes with SC35 in the same compartments.
The spliceosome assembles onto the pre-mRNA through a
series of complexes [as depicted in a recent review on alter-
native splicing (29)]. Pre-mRNAs most likely become incor-
porated co-transcriptionally into an H complex together with
hnRNPs. In the E complex all consensus elements and exon
splicing enhancers (ESEs) are recognized. U1 snRNP binds
the 50 splice site, U2AF
65/35 binds the polypyrimidine tract
and the 30 splice site, and SR proteins bind to ESEs and con-
tact U2AF, U1 snRNP and the branch point. Exons are further
recognized in the A complex where binding of U2snRNP
takes place. U4/U5 and U6 accompany B complex formation.
Finally, catalysis of the splicing reaction takes place in the C
complex following conformational rearrangements of RNA.
We show that XE7 interacts and colocalizes with the SR
protein ASF/SF2 and the SR-related protein ZNF265. ASF/
SF2 is important for almost every step of the splicing process.
The RNA-binding domains of ASF/SF2 speciﬁcally
Figure 6. Colocalization of XE7 with ZNF265LF, ZNF265SF and ASF/SF2. (A) shows HeLa cells cotransfected with pCMV-HA-XE7 and EGFP-ZNF265LF
(B) shows results for cotransfection of pCMV-HA-XE7 and EGFP-ZNF265SF and (C) shows pCMV-HA-XE7 and EGFP-ASF/SF2 cotransfection. The nucleus
was stained with DAPI. Merged image (yellow) indicates colocalization in the nucleus of XE7 with, respectively, ZNF265LF, ZNF265SF, or ASF/SF2. Arrows
denote specific colocalization of XE7 and ZNF265 isoforms in speckles. Scale bar: 10 mm.
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able of binding 50 splice sites (33). ASF/SF2 has also been
shown to interact with the intact U1 snRNP (33,34). It has
been shown that ZNF265 and ASF/SF2 interact with the
U1 snRNP-speciﬁc protein U1-70K (14,33). ZNF265 and
ASF/SF2 also each interact with U2AF
35 (14,35). Since U1
snRNP recognizes the 50 splice site and U2AF the 30 splice
site, the binding of ASF/SF2 and ZNF265 to U1-70K and
U2AF
35 may help in deﬁning splice sites and aid in recruit-
ment of other factors to the pre-mRNA. In contrast to most
factors that bind pre-mRNA directly, XE7 does not have an
RRM domain and then may not bind RNA directly. However,
it is an intriguing possibility that XE7 could stabilize or
strengthen the interaction between the four proteins ASF/
SF2, U1-70K, ZNF265 and U2AF
35. There is of course the
possibility that XE7 does not interact with ASF/SF2 and
ZNF265 at the same time, although it has been shown that
ASF/SF2 can simultaneously interact with U1-70K and
U2AF
35 (35). That the RS domain of XE7 is responsible for
the interaction between XE7 and ZNF265, and ASF/SF2,
is not unexpected. It has been shown previously that both
ASF/SF2 and SC35 interact with U2AF
35 in an RS-domain-
dependent manner (35). Lately, there has been some contro-
versy regarding the function of the RS domain as an exclusive
Figure 7. XE7 influences alternative splice site selection of CD44 and Tra2b1 in HeLa cells in vivo.( A) Structure of the CD44 and Tra2b1 minigenes. Indicated
are: alternative exon (grey) and introns (horizontal lines). Lines connecting the exons indicate the splicing patterns, either including or omitting alternative exons.
(B) Promotion by XE7 of exon 5 inclusion on minigene CD44 and exclusion of exon 2 on Tra2b1 (decrease in b4 form). An increasing amount of pCMV-HA-
XE7 (0–3 mg) was cotransfected with 1 mg of the minigene. Parental vector was added to ensure that similar amounts of cDNAs were transfected. The ethidium
bromide stained polyacrylamide gels are from representative experiments. Sizes of the bands are shown in base pairs (bp) on the right side of the gels. M ¼
100 bp DNA marker. (C) Splicing results of three independent experiments using pCMV-HA-XE7 with minigenes CD44 and Tra2b1. Error bars indicate ± S.E.
All P-values are from t-test vs 0 mg XE7 plasmid.
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showed that the RS domain of SR proteins and U2AF
65
engage directly in protein–RNA interactions . Further experi-
ments are needed to show if the RS-rich region of XE7 inter-
acts with pre-mRNA directly or if it instead forms a kind of
‘glue’ between proteins as postulated above.
We have also shown that XE7 has a signiﬁcant effect on
the alternative splicing of the minigene constructs CD44,
Tra2b1 and SRp20. It seems that XE7 affects splicing
of Tra2b1 pre-mRNA independently of ZNF265 and it is
possible that the two proteins only bind to each other when
they are not functioning as splice factors. Increased levels
of CD44v5 have been found in certain tumors (37–39) and
siRNA-mediated depletion of CD44v5 decreases tumour
cell invasion (40). Since addition of XE7 increases exon 5
inclusion it would be interesting to test if depletion of
this protein results in a decrease of CD44v5 inclusion and
possibly that of tumour cell invasion, as has been shown
for the SR-related protein SRm160 (40). SRm160 often exists
in a complex with SRm300, and both proteins are similar to
XE7 in structure since they contain RS, but not RRM,
domains. The SRm160/300 complex has been shown to pro-
mote splicing through interactions with SR proteins (18), and
we propose that this is also the case for XE7.
The SR protein SRp20 autoregulates its own mRNA by
activating production of transcripts containing exon 4, and
ASF/SF2 suppresses the use of this exon (19). In the present
study we have shown that XE7 has the same effect as ASF/
SF2 on the SRp20 transcript. The RNA binding domain of
ASF/SF2 is responsible for speciﬁcity of exon 4 splicing
(41). Since XE7 does not have an RNA domain it is possible
that XE7 exerts its function by interacting with ASF/SF2 and
functions as a coactivator of splicing, just as the SRm160/300
coactivator subunits described above. XE7 and ASF/SF2 do
Figure 8. XE7 influences alternative splice site selection of SRp20 in synergy with ASF/SF2 in HEK293 cells in vivo.( A) Structure of the SRp20 minigene.
Indicated are: alternative exon (grey) and introns (horizontal lines). Lines connecting the exons indicate the splicing patterns, either including or omitting the
alternative exon. (B) XE7 promotes exon 4 exclusion (i) and addition of ASF/SF2 leads to a further decrease in the form with exon 4 included (ii). An increasing
amount of pCMV-HA-XE7 (0–3 mg) was cotransfected with 1 mg of the minigene. Parental vector was added to ensure that similar amounts of cDNAs were
transfected. One mg of EGFP-ASF/SF2 was added in (ii). The ethidium bromide stained agarose gels are from representative experiments. Sizes of the bands are
shown in bp on the right side of the gels. M ¼ 100 bp DNA marker. (C) Splicing results of three independent experiments using pCMV-HA-XE7 (i) and of
3 independent experiments using pCMV-HA-XE7 with or without (w/o) adding 1 mg ASF/SF2 to the splicing reaction (ii). Error bars indicate ± S.E.
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more deﬁned decrease in exon 4 inclusion when a constant
amount of ASF/SF2 was added to the SRp20-XE7 splicing
reaction. It is possible that the binding of XE7 to ASF/SF2
helps in deﬁning the splice sites on SRp20 and/or recruits
other factors to the pre-mRNA.
Our study has characterized the full-length isoform of
XE7. The alternative (small) isoform has been predicted by
Hillman et al. (42) to undergo nonsense-mediated mRNA
decay (NMD). This eukaryotic mRNA surveillance mechan-
ism detects and degrades mRNAs with premature termination
codons (PTCs), a termination codon being recognized as
premature if it is located more than  50 nt upstream of the
ﬁnal exon. This is the case for the alternative small transcript
of XE7.
Some splicing factors have been shown to autoregulate
their own mRNA by promoting alternative splicing of tran-
scripts containing PTCs, which are then degraded by NMD
(43,44). This is an effective way of ensuring that correct
amounts of splicing proteins are made where needed and
more importantly are not expressed where not needed (or
where they could do harm). Cycloheximide, a chemical inhib-
itor of translation, has been found to inhibit NMD (45), since
NMD depends on translation. Thus it would be interesting to
treat cells with cycloheximide to conﬁrm that the short form
of XE7 is degraded by NMD. It has also been shown that the
RS domain of various SR proteins, amongst them ASF/SF2,
is involved in enhancing NMD (46). Further experiments
may show whether overexpression of ASF/SF2 has the
same effect on XE7.
In summary, we show that XE7 binds to, and colocalizes
with, the SR protein ASF/SF2 and the SR-related protein
ZNF265. Full-length XE7 localizes to the nucleus in all
cells examined and localization is modiﬁed during inhibition
of transcription. We also show that XE7 inﬂuences alternative
splice site selection of each of several pre-mRNA transcripts.
Together, these results show that XE7 is a novel spliceosomal
component, resembling SR-related splicing factors.
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